PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation

Vascular Pharmacology

Volumn 51, Issue 2-3, 2009, Pages 169-174

  Ren, Yusheng ^a   Sun, Chengbo ^a   Sun, Yan ^b   Tan, Hongbing ^a   Wu, Yuechun ^a   Cui, Bo ^c   Wu, Zonggui ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cardiomyocytes; Oxidative stress; PPAR gamma

Indexed keywords

HYDROGEN PEROXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2; ROSIGLITAZONE; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HEART MUSCLE CELL; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN FUNCTION; RAT; UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CASPASE 3; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HYDROGEN PEROXIDE; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS;

EID: 68049121840     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.06.004     Document Type: Article

References (31)

1. Clerk A., Cole S.M., Cullingford T.E., Harrison J.G., Jormakka M., and Valks D.M. Regulation of cardiac myocyte cell death. Pharmacol. Ther. 97 (2003) 223-261
2. Cresci S. Pharmacogenetics of the PPAR genes and cardiovascular disease. Pharmacogenomics 8 (2007) 1581-1595
3. Cui B., Johnson S.P., Bullock N.H., Ali-Osman F., Bigner D.D., and Friedman H.S. Bifunctional DNA Alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. Mol. Pharmacol. 75 (2009) 1356-1363
4. Diep Q.N., Benkirane K., Amiri F., Cohn J.S., Endemann D., and Schiffrin E.L. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J. Mol. Cell. Cardiol. 36 (2004) 295-304
5. Fehlberg S., Gregel C.M., Goke A., and Goke R. Bisphenol A diglycidyl ether-induced apoptosis involves Bax/Bid-dependent mitochondrial release of apoptosis-inducing factor (AIF), cytochrome c and Smac/DIABLO. Br. J. Pharmacol. 139 (2003) 495-500
6. Frangogiannis N.G., Shimoni S., Chang S.M., Ren G., Shan K., Aggeli C., Reardon M.J., Letsou G.V., Espada R., Ramchandani M., Entman M.L., and Zoghbi W.A. Evidence for an active inflammatory process in the hibernating human myocardium. Am. J. Pathol. 160 (2002) 1425-1433
7. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R.A., Martinez G., Inestrosa N.C., and Bronfman M. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 282 (2007) 37006-37015
8. Gross A., McDonnell J.M., and Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13 (1999) 1899-1911
9. Hall G., Hasday J.D., and Rogers T.B. Regulating the regulator: NF-kappaB signaling in heart. J. Mol. Cell. Cardiol. 41 (2006) 580-591
10. Han S., and Roman J. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?. Anticancer Drugs 18 (2007) 237-244
11. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
12. Kersten S., and Wahli W. Peroxisome proliferator activated receptor agonists. Exs. 89 (2000) 141-151
13. Khan M., Varadharaj S., Shobha J.C., Naidu M.U., Parinandi N.L., Kutala V.K., and Kuppusamy P. C-phycocyanin ameliorates doxorubicin-induced oxidative stress and apoptosis in adult rat cardiomyocytes. J. Cardiovasc. Pharmacol. 47 (2006) 9-20
14. Khor G.L. Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac. J. Clin. Nutr. 10 (2001) 76-80
15. Krack A., Sharma R., Figulla H.R., and Anker S.D. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur. Heart J. 26 (2005) 2368-2374
16. Kuusisto J., Andrulionyte L., and Laakso M. Atherosclerosis and cardiovascular risk reduction with PPAR agonists. Curr. Atheroscler. Rep. 9 (2007) 274-280
17. Lehrke M., and Lazar M.A. The many faces of PPARgamma. Cell 123 (2005) 993-999
18. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323 (1990) 236-241
19. Lopez-Neblina F., Toledo A.H., and Toledo-Pereyra L.H. Molecular biology of apoptosis in ischemia and reperfusion. J. Invest. Surg. 18 (2005) 335-350
20. Lou H., Kaur K., Sharma A.K., and Singal P.K. Adriamycin-induced oxidative stress, activation of MAP kinases and apoptosis in isolated cardiomyocytes. Pathophysiology 13 (2006) 103-109
21. Nikolaidis L.A., and Levine T.B. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure?. Cardiol. Rev. 12 (2004) 158-170
22. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., and Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6668-6673
23. Schnall P., Belkic K., Landsbergis P., and Baker D. Why the workplace and cardiovascular disease?. Occup. Med. 15 (2000) 1-6 (iii)
24. Scott L.J., Mohlke K.L., Bonnycastle L.L., Willer C.J., Li Y., Duren W.L., Erdos M.R., Stringham H.M., Chines P.S., Jackson A.U., Prokunina-Olsson L., Ding C.J., Swift A.J., Narisu N., Hu T., Pruim R., Xiao R., Li X.Y., Conneely K.N., Riebow N.L., Sprau A.G., Tong M., White P.P., Hetrick K.N., Barnhart M.W., Bark C.W., Goldstein J.L., Watkins L., Xiang F., Saramies J., Buchanan T.A., Watanabe R.M., Valle T.T., Kinnunen L., Abecasis G.R., Pugh E.W., Doheny K.F., Bergman R.N., Tuomilehto J., Collins F.S., and Boehnke M. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316 (2007) 1341-1345
25. Sertznig P., Seifert M., Tilgen W., and Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J. Cell. Physiol. 212 (2007) 1-12
26. Seta Y., Shan K., Bozkurt B., Oral H., and Mann D.L. Basic mechanisms in heart failure: the cytokine hypothesis. J. Card. Fail. 2 (1996) 243-249
27. Smith D. Cardiovascular disease: a historic perspective. Jpn. J. Vet. Res. 48 (2000) 147-166
28. Stommel J.M., and Wahl G.M. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23 (2004) 1547-1556
29. Suzuki K., Kostin S., Person V., Elsasser A., and Schaper J. Time course of the apoptotic cascade and effects of caspase inhibitors in adult rat ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 33 (2001) 983-994
30. Wu J.S., Lin T.N., and Wu K.K. Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J. Cell. Physiol. 220 (2009) 58-71
31. Yu S., and Reddy J.K. Transcription coactivators for peroxisome proliferator-activated receptors. Biochim. Biophys. Acta 1771 (2007) 936-951